United States
Healthcare

June 1, 2024

Edward Woo, CFA
(561) 327-9435
ewoo@ascendiant.com

Plus Therapeutics, Inc.

Reports Q1 with solid progress on clinical trials. Upcoming key milestones in 2024/25 should be positive for stock. Lowering P/T to $21.

COMPANY UPDATE

Rating: BUY

Ticker: PSTV

Price: $2.21

Target: $21.00 (from $22)

Q1 results: Plus recently (on May 15) reported its Q1 2024 (ending March) results. Revenue was $1.7 million, compared with our and consensus estimates of $1.7 million. EPS was $(0.75) (net loss of $3.3 million), compared with our estimates of $(0.72) and consensus of $(1.09). There was no Q1 guidance.

No guidance: Management did not provide 2024 guidance, but we believe current quarterly cash burn of ~$3 million is a reasonable near-term rate.

Adjusting estimates: We are maintaining our 2024 revenue estimates (grant revenue) of $7 million, but adjusting it for EPS to $(1.69) from $(2.82).

Focus on RNL for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda), is initially being developed for recurrent glioblastoma (GBM) but has expanded to other cancers indications. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.

Major grant win: In August 2022, the company received a $18 million grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to study leptomeningeal metastases. In April 2024, the company received a $3 million grant from the U.S. Department of Defense to study pediatric brain cancer.

GBM Phase 2/3 pivotal trial: The company announced (in Nov. 2021) positive interim data from its ReSPECT-GBM Phase 1 clinical trial. RNL is well-tolerated with favorable overall survival in adult patients at higher absorbed radiation doses (greater than 100 Gy). The company has moved to the next Phase 2/3 pivotal trial for RNL in recurrent glioblastoma in January 2023. Recent interim data presented at the Society for NeuroOncology Annual Meeting in November 2023 were also positive.

RNL for LM trial: The clinical study (ReSPECT-LM Phase 1) for RNL for the treatment of leptomeningeal metastases (LM) is ongoing. Cohort 5 has completed dosing in March 2024. Initial data from the Phase 1/Part A has been positive, and key interim data will be presented in August 2024 and November 2024. As part of its LM trial, in May 2024, it acquired all assets to exclusively commercialize the novel leptomeningeal metastases diagnostic, CNSide.

PBC trial planned: RNL is expected to treat additional oncology indications, with a near term focus on GBM, leptomeningeal metastases (LM), and pediatric brain cancer (PBC). The company aims to file an IND in 2024 (with clinical trials to start shortly after) for PBC.

Remain long term positive: We believe that Plus is progressing well in its drug development with key milestones and data points expected in 2024/25. Key interim data will be presented in 2H 2024 (at key upcoming scientific conferences in June, August, and November).

Balance sheet: In Q1, Plus had $3 million in cash and $4 million in debt. In May (current Q2), the company raised ~$7 million selling stock. We believe the company has enough cash through 2025.

Risk/reward positive: Maintaining our BUY rating, but lowering our 12-month price target to $21 from $22, which is based on a NPV analysis. We believe this is reasonable to reflect high clinical trial risks, offset by very large market opportunities.

Company Description

Based in Austin, TX, Plus Therapeutics is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs.

Stock Data

Exchange:	NasdaqGS
52-week Range:	$0.97 –4.04
Shares Outstanding (million):	9
Market cap ($million):	$20
EV ($million):	$21
Debt ($million):	$4
Cash ($million):	$3
Avg. Daily Trading Vol. ($million):	$0.2
Float (million shares):	4
Short Interest (million shares):	~0
Dividend, annual (yield):	$0 (NA%)

Revenues (US$ million)

	2024E (Cur.)	2024E (Old)	2025E (Cur.)	2025E (Old)
Q1 Mar	2A	2E	2E	
Q2 Jun	2E		2E	
Q3 Sep	2E		2E	
Q4 Dec	2E		1E	
Total	**7E**		**5E**	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	2024E (Cur.)	2024E (Old)	2025E (Cur.)	2025E (Old)
Q1 Mar	(0.75)A	(0.72)E	(0.38)E	(0.73)E
Q2 Jun	(0.37)E	(0.71)E	(0.38)E	(0.72)E
Q3 Sep	(0.37)E	(0.69)E	(0.37)E	(0.70)E
Q4 Dec	(0.36)E	(0.70)E	(0.49)E	(0.92)E
Total	**(1.69)E**	**(2.82)E**	**(1.61)E**	**(3.08)E**
P/E	N/A		N/A	

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 19.

Exhibit 1: Plus Therapeutics



Source: Company report.

Exhibit 2: Plus's Product Pipeline (as of March 2024)



Source: Company report.

Exhibit 3: Malignant Gliomas: Disease & Market Assessment



Source: Company report.

Exhibit 4: ReSPECT-GBM Timeline (as of March 2024)



Source: Company report.

Exhibit 5: Medical Radionuclides



PLUS' Technology Provides Better Patient Experience for CNS Cancer Care

Radiotherapy in a short inpatient hospitalization or single outpatient visit

Personalized Treatment Planning → SoC Biopsy & Catheter Placement → Drug Infusion → Patient Monitoring

Indication	Week Prior to Treatment	Day 1	Day 2	Day 3
• Recurrent GBM • Ped Ependymoma • Ped HGG	MRI imaging to assess & plan catheter number, trajectory & flow rate	Standard of care biopsy followed by catheter placement in OR	Single ~4-hour infusion & real-time imaging in hospital Nuclear Medicine department	Catheter removal & patient discharged
Leptomeningeal Metastases	CSF flow study to confirm no flow obstruction	Single 5-minute injection in outpatient setting		

Source: Company report.

Exhibit 6: Novel Rhenium NanoLiposome (RNL)



Source: Company report.

Exhibit 7: RNL ReSPECT-GBM Clinical Trial (as of May 2023)

ReSPECT-GBM Phase 1/2 Clinical Trial Design

Multi-center, sequential cohort, open-label, volume & dose finding study of the safety, tolerability, & distribution of ^{186}RNL given by convection-enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment.

- Single arm, prospective Phase 1/2 study utilizing a modified Fibonacci dose escalation scheme Phase 1, followed by an expansion at the designated recommended Phase 2 dose (RP2D)
- Maximum number of subjects: 55
- Current status: 23 subjects enrolled across 7 dose cohorts at 3 sites
- Supported by a National Institutes of Health (NIH) grant through Phase 2

Convection-Enhanced Delivery

NIH National Institutes of Health | UT Health San Antonio | UTSouthwestern Medical Center | The University of Texas MD Anderson Cancer Center Making Cancer History

Source: Company report.

Exhibit 8: RNL ReSPECT-GBM Clinical Trial Progress (as of March 2024)

Comparative Survival Data

ReSPECT-GBM vs. Real World Experience

- Meta analysis of ~700 rGBM patients
- Plus and Medidata conducted 2 RWE control arms with propensity match rGBM patients to Plus Phase 1 data
- Propensity matching- baseline characteristics were well-aligned
- 38% improvement over RWE control for Phase 1 (to RP2D)
- Respect GBM phase 1 N = 21, phase 2 N = 15 (6 alive**)
- 113% improvement over RWE control in patients receiving therapeutic dose radiation (>100Gy)
- 63% improvement in Phase 2 patients (n=15 of 34 planned patients)



Source: Company report.

Exhibit 9: RNL ReSPECT-GBM Phase 1 Clinical Trial Interim Data (as of September 2022)

ReSPECT-GBM Safety Results

^{186}RNL Appears to be Safe & Well Tolerated

Thus far, in the Phase 1 study of 23 subjects in 8 dosing cohorts with recurrent glioblastoma receiving a single dose of ^{186}RNL:

+ There have been no dose limiting toxicities.
+ Most AEs reported were mild or moderate (Grade 1 or 2) in intensity.
+ Most AEs were considered causally unrelated to ^{186}RNL except scalp discomfort, which was considered related to the surgical procedure.
+ Serious adverse events:

Serious Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Osteonecrosis (Left Shoulder)	0	0	1	0	0	1
Seizure	0	1	2	0	0	3
Vasogenic cerebral edema	0	0	2	0	0	2
Pneumonia	0	0	1	0	0	1

Comparative Survival Data

ReSPECT-GBM vs. 'Best' Real World Data

Trial or Data Source	Number Patients	Median Overall Survival
Meta-analysis*- Bevucizamab	~700	32.1 weeks (7 months)
MEDS- Bevacizumab	163	7.9 months
MEDS- CED	636	8.4 months
ReSPECT-GBM Phase 1 Dose Escalation		
All	21	11 months
<100Gy	9	6 months
>100Gy	11	17 months

Source: Company report.

Exhibit 10: New RNL ReSPECT-GBM Phase 2 Clinical Trial Interim Data (as of November 20, 2023)

Key Highlights from the ReSPECT-GBM Phase 2 Trial

ReSPECT-GBM is an ongoing, first-in-human, open-label, Phase 1/2 study investigating dose escalation and other delivery parameters (i.e., number of catheters (1-5), infusion rates, drug volumes, and drug concentrations) to determine the maximum tolerated dose (MTD), maximum feasible dose (MFD), safety, and efficacy of rhenium (^{186}Re) obisbemeda in recurrent adult glioma (IND 116117).

The primary objective of the Phase 2 study is to assess overall survival (OS) following rhenium (^{186}Re) obisbemeda administration. As of November 14, 2023, 15 patients with rGBM have been treated with rhenium (^{186}Re) obisbemeda at a dose of 22.3 mCi delivered directly to the tumor by Convection Enhanced Delivery (CED).

- In 15 treated patients, mOS is 13 months (95% CI 5 months). Currently, 9 out of the 15 treated patients remain alive.
- Median PFS is 11 months (95% CI 6-11 months).
- The average percent of treated tumor across all 15 patients was 87.2% at 120 hours, with 13/15 patients receiving greater than or equal 70% tumor volume coverage by the drug and ≥100 Gy absorbed dose to the tumor.
- Advanced longitudinal imaging analysis supports the observed efficacy signal of rhenium (^{186}Re) obisbemeda.
- Rhenium (^{186}Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.

Source: Company report.

Exhibit 11: ReSPECT-LM Trial

^{186}RNL in Leptomeningeal Cancer

Disease Background

+ Leptomeningeal cancer, also known as carcinomatosis, is a cancer that starts in one part of the body spreads to the leptomeningeal lining of the brain and spinal cord surrounding the cerebrospinal fluid (CSF) space.

100 nm NanoLiposomes in CSF

+ Circulate feely throughout the CSF.
+ Migrate to meningeal surfaces where LMC is located.
+ Have an extended half life - several weeks vs. hours with unencapsulated drugs.
+ Safe & effective in preclinical models

Phase 1 Clinical Trial

+ 2-part dose escalation trial
+ 1st site at UTSW enrolling
+ Planned 5 sites
+ 5 cc delivered via Omaya reservoir
+ Feasibility & safety

PLUS THERAPEUTICS



Delivery via Standard Ommaya Reservoir

ReSPECT-LM Phase 1 Clinical Trial Design

A two-part, multi-center Phase 1 study to determine the maximum tolerated dose/ maximum feasible dose, safety, & efficacy of single dose Rhenium-186 NanoLiposome (^{186}RNL) administered via the intraventricular route for leptomeningeal metastases (LM).

Primary Objective

Safety & tolerability of a single dose of ^{186}RNL by the intraventricular route & to identify a MTD &/or MFD

Secondary Objectives

+ PK & dosimetry profile of a single dose of ^{186}RNL when administered intraventricularly via Ommaya reservoir
+ Develop a multiple dosing strategy of ^{186}RNL for subsequent clinical trials
+ Overall Response Rate (ORR)
+ Duration of Response (DoR)
+ Progression-Free Survival (PFS)
+ Overall Survival (OS)

Delivery via Ommaya Reservoir

Primary Endpoints

+ Incidence & severity of adverse events (AE) & serious adverse events (SAE)
+ Incidence of dose limiting toxicities (DLT)

UT Health San Antonio

UTSouthwestern Medical Center

Source: Company report.

Exhibit 12: ReSPECT-LM Clinical Development Path for LM (Breast & Lung CA) (as of March 2024)



Source: Company report.

Exhibit 13: ReSPECT-PBC Clinical Development Path for Pediatric Brain Cancer (PBC) (as of June 2023)



Source: Company report.

Exhibit 14: Plus's 188RNL-BAM







Source: Company report.

Exhibit 15: ReSPECT LM Treatment Response Data (as of March 2024)

ReSPECT-LM Phase 1 Treatment Response Data

Median overall survival and percent CSF tumor cell change show potential treatment effect





- N = 13 evaluable patients
- Max percent reduction in CSF tumor cells at D28 was 90%
- Average of 53% CSF tumor cell reduction at D28

- N = 10 patients, cohorts 1-3
- mOS was 10 months*
- 5 of these patients remain alive**

Source: Company report.

Exhibit 16: Plus's Key Q1 and Recent Milestones (as of May 15, 2024)

Q1 2024 AND RECENT HIGHLIGHTS AND MILESTONE ACHIEVEMENTS

- Closed private placement financing on May 9, 2024, for initial gross proceeds of $7.25 million and aggregate proceeds of up to $19.25 million
- Received notice of award for a $3 million grant from the United States Department of Defense, subject to customary documentation and approvals, to fund Phase 1 trial of rhenium (^{186}Re) obisbemeda in children with high-grade glioma and ependymoma
- Acquired all assets required to exclusively commercialize the novel leptomeningeal metastases diagnostic, CNSide. Additional detail on the acquisition can be found here
- Strengthened management team with appointments of neuro-oncologist Andrew Brenner, M.D. as a part- time consultant and Barbara Blouw, Ph.D. as Vice President of Clinical Affairs
- Completed validation and clinical implementation of CNSide tumor cell enumeration assay as an exploratory endpoint in the ReSPECT-LM trial
- Presented at the following scientific conferences:
  - **National Comprehensive Cancer Network (NCCN) 2024 Annual Conference** (April 5-7) on updated initial safety and feasibility of rhenium (186Re) obisbemeda in the ReSPECT-LM phase 1 trial
  - **2024 NMN (Nuclear Medicine and Neuro-oncology) Symposium** (April 26-27) on:
    - Update Report of the ReSPECT-GBM Phase 1/2 Dose Escalation Trial of Rhenium (^{186}Re) Obisbemeda (Rhenium-186 Nanoliposome, ^{186}RNL) in Recurrent Glioma via Convection Enhanced Delivery (CED)
    - Rhenium (^{186}Re) Obisbemeda (^{186}RNL) in Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (Cm): ReSPECT-GBM Phase 2 Trial Update
    - ReSPECT-LM Phase 1 Dose Escalation Trial of Rhenium (^{186}Re) Obisbemeda

Source: Company report.

Exhibit 17: Plus's Upcoming Milestones (as of May 15, 2024)

UPCOMING EXPECTED EVENTS AND MILESTONES

- Presentations planned for the following upcoming scientific conferences:
  - **SNMMI (Society of Nuclear Medicine & Molecular Imaging) Annual Meeting** (June 8-11, 2024)
    - Accepted abstracts:
      - Rhenium (^{186}Re) obisbemeda (^{186}RNL) in leptomeningeal metastases (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility through Cohorts 1-4.
      - Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals
  - **SNO/ASCO (Society for Neuro-Oncology / American Society of Clinical Oncology) CNS Metastases Conference** (August 8-10, 2024)
    - Submitted abstracts:
      - Phase 1 Dose Escalation of Rhenium (^{186}Re) obisbemeda (^{186}RNL) for the Treatment of Leptomeningeal Metastases: Ongoing Clinical Study Update for Initial Safety and Feasibility
      - CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (FORESEE Study, NCT05414123)
      - The CNSide CSF Tumor Cell detection platform is a feasible, clinically relevant and scalable platform for disease management for patients with Leptomeningeal Disease
  - **SNO Annual Conference** (November 22-26, 2024); planned comprehensive update on the Phase 1 dose escalation ReSPECT-LM trial for leptomeningeal metastases
  - Present update for the Phase 2 ReSPECT-GBM trial for recurrent adult glioblastoma at one of the key neurosurgery or neuro-oncology meetings in late 2024
- FDA granted ReSPECT-LM Type C meeting for a multi-dose Phase 1 dose escalation study, scheduled for June 10, 2024
- Anticipate FDA feedback in second half 2024 for ReSPECT-PBC investigational new drug application (IND) for pediatric ependymoma and high-grade glioma, with the aim of attaining IND approval
- Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated and recommended Phase 2 dose, and determine the multiple dosing regime
- Report results of preclinical combination studies of rhenium (^{186}Re) obisbemeda with PD-1 and PD-L1 checkpoint inhibitors
- Secure contract with second GMP manufacturing supplier to ensure ample rhenium (^{186}Re) obisbemeda supply for pivotal trials and commercial readiness

Source: Company report.

Exhibit 18: Plus Therapeutics, Inc. Stock Price (Five Years)



Source: https://bigcharts.marketwatch.com/

Exhibit 19: Consensus Expectations (as of May 15, 2024)

	Revenue (mil)			EPS	
	2024E	2025E		2024E	2025E
Q1 Mar	$1.7E		Q1 Mar	$(1.09)E	
Q2 Jun	$1.7E		Q2 Jun	$(0.75)E	
Q3 Sep			Q3 Sep		
Q4 Dec			Q4 Dec		
Total	$5.1E	$2.9E	Total	$(2.41)E	$(2.39)E

**Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.*

Source: Company report, LSEG, and Ascendiant Capital Markets estimates

FINANCIAL MODEL

Plus Therapeutics, Inc.

Income Statement ($ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Sales Revenue					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
License/grants/other			0.1	0.2	0.2	0.5	1.9	1.2	1.3	4.9	1.7	1.6	1.6	1.7	6.6	1.5	1.5	1.5	0.5	5.0
Total Revenue	**0.0**	**0.0**	**0.1**	**0.2**	**0.2**	**0.5**	**1.9**	**1.2**	**1.3**	**4.9**	**1.7**	**1.6**	**1.6**	**1.7**	**6.6**	**1.5**	**1.5**	**1.5**	**0.5**	**5.0**
Cost of Revenues					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	0.0	0.0	0.1	0.2	0.2	0.5	1.9	1.2	1.3	4.9	1.7	1.6	1.6	1.7	6.6	1.5	1.5	1.5	0.5	5.0
Research and development	1.8	2.8	2.9	2.1	9.7	3.0	1.4	2.5	2.8	9.7	2.8	3.0	3.0	3.0	11.8	3.0	3.0	3.0	3.0	12.0
Selling and marketing					0.0					0.0					0.0					0.0
General and administrative	2.1	2.3	2.2	3.6	10.2	2.2	1.9	2.0	2.4	8.5	2.2	2.0	2.0	2.0	8.2	2.0	2.0	2.0	2.0	8.0
Restructuring, litigation, and other					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total operating expenses	3.9	5.1	5.2	5.7	19.9	5.2	3.3	4.5	5.2	18.2	5.0	5.0	5.0	5.0	20.0	5.0	5.0	5.0	5.0	20.0
Operating income (loss)	**(3.9)**	**(5.1)**	**(5.1)**	**(5.6)**	**(19.7)**	**(4.7)**	**(1.5)**	**(3.3)**	**(3.9)**	**(13.3)**	**(3.3)**	**(3.4)**	**(3.4)**	**(3.3)**	**(13.4)**	**(3.5)**	**(3.5)**	**(3.5)**	**(4.5)**	**(15.0)**
Interest income (expense)	(0.2)	(0.2)	(0.1)	(0.1)	(0.6)	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2
Other income (expense)	0.0				0.0	(0.0)			0.0	0.0		0.0	0.0	(0.1)	(0.1)	0.0	0.0	0.0	(0.1)	(0.1)
Income before income taxes	(4.1)	(5.3)	(5.2)	(5.7)	(20.3)	(4.8)	(1.5)	(3.2)	(3.8)	(13.3)	(3.3)	(3.4)	(3.4)	(3.3)	(13.3)	(3.5)	(3.5)	(3.5)	(4.5)	(14.9)
Income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(4.1)	(5.3)	(5.2)	(5.7)	(20.3)	(4.8)	(1.5)	(3.2)	(3.8)	(13.3)	(3.3)	(3.4)	(3.4)	(3.3)	(13.3)	(3.5)	(3.5)	(3.5)	(4.5)	(14.9)
Nonrecurring/noncash adjustments					0.0					0.0					0.0					0.0
Net income (pro forma)	**(4.1)**	**(5.3)**	**(5.2)**	**(5.7)**	**(20.3)**	**(4.8)**	**(1.5)**	**(3.2)**	**(3.8)**	**(13.3)**	**(3.3)**	**(3.4)**	**(3.4)**	**(3.3)**	**(13.3)**	**(3.5)**	**(3.5)**	**(3.5)**	**(4.5)**	**(14.9)**
EBITDA	(3.6)	(4.8)	(4.8)	(5.3)	(18.5)	(4.4)	(1.2)	(2.9)	(3.6)	(12.0)	(3.0)	(2.6)	(2.6)	(2.5)	(10.7)	(2.7)	(2.7)	(2.7)	(3.7)	(11.8)
Shares, Basic	1.4	1.5	1.8	2.3	1.8	2.3	2.5	3.2	4.5	3.1	4.3	9.0	9.1	9.1	7.9	9.1	9.2	9.3	9.3	9.2
Shares, Diluted	1.4	1.5	1.8	2.3	1.8	2.3	2.5	3.2	4.5	3.1	4.3	9.0	9.1	9.1	7.9	9.1	9.2	9.3	9.3	9.2
EPS Basic (Pro forma)	**($2.87)**	**($3.56)**	**($2.85)**	**($2.50)**	**($11.58)**	**($2.07)**	**($0.59)**	**($1.00)**	**($0.85)**	**($4.24)**	**($0.75)**	**($0.37)**	**($0.37)**	**($0.36)**	**($1.69)**	**($0.38)**	**($0.38)**	**($0.37)**	**($0.49)**	**($1.61)**
EPS Diluted (Pro forma)	($2.87)	($3.56)	($2.85)	($2.50)	($11.58)	($2.07)	($0.59)	($1.00)	($0.85)	($4.24)	($0.75)	($0.37)	($0.37)	($0.36)	($1.69)	($0.38)	($0.38)	($0.37)	($0.49)	($1.61)
Margins																				
Gross margin (ex. other rev)																				
Research and development																				
Selling and marketing																				
General and administrative																				
Operating margin																				
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	NM	NM	-7149%	-3747%	-9051%	-950%	-80%	-260%	-290%	-271%	-194%	-210%	-210%	-195%	-202%	-231%	-231%	-231%	-902%	-298%
Y/Y % change																				
Total Revenue																				
Gross margin																				
Research and development	58%	156%	98%	34%	82%	67%	-50%	-15%	31%	0%	-7%	111%	20%	7%	21%	9%	0%	0%	0%	2%
Selling and marketing																				
General and administrative	58%	56%	12%	76%	49%	5%	-16%	-10%	-34%	-17%	-1%	4%	0%	-16%	-4%	-10%	0%	0%	0%	-3%
Operating income (loss)	58%	99%	46%	41%	58%	20%	-71%	-36%	-31%	-32%	-30%	128%	5%	-15%	1%	6%	3%	3%	36%	12%
Net income (loss)	51%	89%	40%	36%	51%	17%	-72%	-38%	-33%	-34%	-32%	127%	4%	-13%	0%	6%	3%	3%	36%	12%
EPS Diluted (Pro forma)	-42%	-4%	-32%	-38%	-30%	-28%	-83%	-65%	-66%	-63%	-64%	-37%	-63%	-57%	-60%	-50%	1%	1%	33%	-4%

Source: Company reports and Ascendiant Capital Markets estimates. *Reflects a 1:15 reverse stock split in May 2023*

Plus Therapeutics, Inc.

Balance Sheet ($ mils) Fiscal Year End: December 31	Mar-22 Q1A	Jun-22 Q2A	Sep-22 Q3A	Dec-22 Q4A	Mar-23 Q1A	Jun-23 Q2A	Sep-23 Q3A	Dec-23 Q4A	Mar-24 Q1A	Jun-24 Q2E	Sep-24 Q3E	Dec-24 Q4E	Mar-25 Q1E	Jun-25 Q2E	Sep-25 Q3E	Dec-25 Q4E
Assets																
Cash and cash equivalents	21.2	18.1	20.3	18.1	12.7	10.9	11.0	8.6	2.9	6.6	10.3	7.0	7.1	3.7	0.3	(4.2)
Short term investments									0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Accounts receivable, net						0.7	0.1			0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventories										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred financing costs										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.9	0.8	0.6	3.7	0.9	0.8	0.5	1.3	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Total current assets	22.1	18.9	20.9	21.8	13.6	12.4	11.6	9.8	4.2	7.9	11.6	8.3	8.4	5.0	1.6	(2.9)
Property and equipment, net	1.6	1.6	1.5	1.3	1.3	1.1	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5
Restricted cash										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Goodwill and intangibles	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Total assets	**24.5**	**21.3**	**23.1**	**23.9**	**15.6**	**14.2**	**13.3**	**11.4**	**5.6**	**9.3**	**12.9**	**9.6**	**9.6**	**6.2**	**2.7**	**(1.8)**
Liabilities and stockholders' equity																
Accounts payable	3.2	5.3	5.7	10.1	6.5	6.6	6.1	6.6	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4
Accrued expenses	0.1	0.1	0.1	0.1	1.2	0.1	0.1	0.1	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Term fee/divest obligations										0.0	0.0	0.0	0.0	0.0	0.0	0.0
JV purchase obligation										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short term debt	1.6	1.6	1.6	1.6	5.1	4.7	4.3	4.0	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.6
Total current liabilities	**4.9**	**7.0**	**7.4**	**11.9**	**12.8**	**11.4**	**10.5**	**10.7**	**10.4**	**10.4**	**10.4**	**10.4**	**10.4**	**10.4**	**10.4**	**10.4**
Deferred revenue										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.2	0.2	0.2	1.8	0.2	0.1	0.1	2.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Warrant liabilities										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred rent and other										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long term debt	4.7	4.4	4.1	3.8						0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	**5.0**	**4.6**	**4.3**	**5.6**	**0.2**	**0.1**	**0.1**	**2.0**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	465.6	466.0	472.9	473.6	474.6	476.1	479.3	479.1	478.9	478.9	478.9	478.9	478.9	478.9	478.9	478.9
Retained earnings	(451.0)	(456.3)	(461.5)	(467.2)	(472.0)	(473.5)	(476.7)	(480.5)	(483.8)	(487.1)	(490.5)	(493.8)	(497.3)	(500.7)	(504.2)	(508.7)
Accumulated other comprehensive income										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other										7.0	14.0	14.0	17.5	17.5	17.5	17.5
Total stockholders' equity	**14.6**	**9.7**	**11.4**	**6.4**	**2.7**	**2.7**	**2.6**	**(1.3)**	**(4.8)**	**(1.2)**	**2.4**	**(0.9)**	**(0.8)**	**(4.3)**	**(7.8)**	**(12.3)**
Total stockholders' equity and liabil	**24.5**	**21.3**	**23.1**	**23.9**	**15.6**	**14.2**	**13.3**	**11.4**	**5.6**	**9.3**	**12.9**	**9.6**	**9.6**	**6.2**	**2.7**	**(1.8)**

Balance Sheet Drivers

	Mar-22 Q1A	Jun-22 Q2A	Sep-22 Q3A	Dec-22 Q4A	Mar-23 Q1A	Jun-23 Q2A	Sep-23 Q3A	Dec-23 Q4A	Mar-24 Q1A	Jun-24 Q2E	Sep-24 Q3E	Dec-24 Q4E	Mar-25 Q1E	Jun-25 Q2E	Sep-25 Q3E	Dec-25 Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	$10.21	$6.52	$6.23	$2.84	$1.15	$1.06	$0.81	-$0.30	-$1.12	-$0.13	$0.27	-$0.10	-$0.11	-$0.47	-$0.84	-$1.32
Cash per Share (diluted)	$14.81	$12.19	$11.08	$7.99	$5.48	$4.34	$3.41	$1.90	$0.75	$0.77	$1.16	$0.81	$0.94	$0.44	$0.07	-$0.42
Net cash per Share (diluted)	$10.40	$8.13	$7.95	$5.61	$3.30	$2.47	$2.06	$1.02	-$0.08	$0.37	$0.77	$0.41	$0.49	$0.05	-$0.32	-$0.80

Source: Company reports and Ascendiant Capital Markets estimates

Plus Therapeutics, Inc.

Cash Flow Statement ($ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																				
Net income	(4.1)	(5.3)	(5.2)	(5.7)	(20.3)	(4.8)	(1.5)	(3.2)	(3.8)	(13.3)	(3.3)	(3.4)	(3.4)	(3.3)	(13.3)	(3.5)	(3.5)	(3.5)	(4.5)	(14.9)
Depreciation and amortization	0.1	0.2	0.2	0.2	0.6	0.2	0.2	0.2	0.2	0.6	0.2	0.3	0.3	0.3	1.1	0.3	0.3	0.3	0.3	1.2
Amortization of financing costs	0.1	0.1	0.1	0.2	0.5	0.1	0.0	0.0	0.0	0.2	0.0				0.0					0.0
JV accretion					0.0					0.0					0.0					0.0
A/R reserves					0.0					0.0					0.0					0.0
Inventory reserves					0.0					0.0					0.0					0.0
Stock comp	0.2	0.2	0.1	0.1	0.6	0.1	0.1	0.2	0.1	0.6	0.1	0.5	0.5	0.5	1.6	0.5	0.5	0.5	0.5	2.0
Other gains/losses					0.0	0.0				0.0					0.0					0.0
Impairments					0.0					0.0					0.0					0.0
Warrant revaluation	(0.0)	0.0	0.0	(0.0)	(0.0)					0.0					0.0					0.0
Other	(0.0)	(0.0)	0.0	0.0	0.0		0.1	0.0	0.0	0.1	0.0	(0.5)	(0.5)	(0.5)	(1.5)	(0.5)	(0.5)	(0.5)	(0.5)	(2.0)
Changes in operating assets and liabilities:																				
Accounts receivable					0.0			(0.1)	0.1	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other assets	0.5	0.1	0.2	(3.1)	(2.4)	2.8	(0.6)	1.0	(0.8)	2.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
Accounts payable and accrued exp	(0.7)	2.2	0.4	4.5	6.5	(3.6)	0.0	(0.5)	0.4	(3.7)	(0.0)	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0
Deferred revenue					0.0	(0.5)	(1.1)		1.9	0.3		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred rent					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities				1.5	1.5	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(1.7)				(1.7)					0.0
Net cash (used in) provided by oper	**(3.9)**	**(2.6)**	**(4.2)**	**(2.2)**	**(13.0)**	**(5.8)**	**(2.8)**	**(2.4)**	**(1.9)**	**(12.9)**	**(4.5)**	**(3.1)**	**(3.1)**	**(3.0)**	**(13.6)**	**(3.2)**	**(3.2)**	**(3.2)**	**(4.2)**	**(13.7)**
Cash flow from investing activities																				
Purchases of property and equipmen	(0.2)	(0.1)	(0.0)	(0.1)	(0.5)	(0.1)	(0.0)	(0.0)	(0.0)	(0.2)	(0.0)	(0.3)	(0.3)	(0.3)	(0.8)	(0.3)	(0.3)	(0.3)	(0.3)	(1.0)
Purchases of short-term investments					0.0					0.0	(0.3)				(0.3)					0.0
Acquisitions	(0.1)	(0.3)	0.3	0.1	0.0					0.0					0.0					0.0
Other	(0.3)	0.3	(0.3)		(0.3)					0.0					0.0					0.0
Net cash used in investing activities	**(0.6)**	**(0.1)**	**(0.0)**	**(0.0)**	**(0.8)**	**(0.1)**	**(0.0)**	**(0.0)**	**(0.0)**	**(0.2)**	**(0.4)**	**(0.3)**	**(0.3)**	**(0.3)**	**(1.1)**	**(0.3)**	**(0.3)**	**(0.3)**	**(0.3)**	**(1.0)**
Cash flow from financing activities																				
Issuance of debt	(0.4)	(0.4)	(0.4)	(0.4)	(1.6)	(0.4)	(0.4)	(0.4)	(0.4)	(1.6)	(0.4)	0.0	0.0	0.0	(0.4)	0.0	0.0	0.0	0.0	0.0
JV payments					0.0					0.0					0.0					0.0
Issuance of stock	7.7	0.0	6.8	0.5	15.1	0.9	1.4	2.9	(0.1)	5.1	(0.4)				(0.4)					0.0
Financing costs					0.0					0.0					0.0					0.0
Issuance of warrants					0.0					0.0					0.0					0.0
Proceeds from stock option exercises					0.0					0.0					0.0					0.0
Dividends					0.0					0.0					0.0					0.0
Other					0.0					0.0		7.0	7.0		14.0	3.5				3.5
Cash provided by (used in) financin	**7.3**	**(0.4)**	**6.4**	**0.1**	**13.5**	**0.5**	**1.0**	**2.5**	**(0.5)**	**3.4**	**(0.8)**	**7.0**	**7.0**	**0.0**	**13.2**	**3.5**	**0.0**	**0.0**	**0.0**	**3.5**
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
Net increase (decrease) in cash and	**2.8**	**(3.1)**	**2.2**	**(2.1)**	**(0.3)**	**(5.4)**	**(1.8)**	**0.1**	**(2.5)**	**(9.6)**	**(5.7)**	**3.7**	**3.7**	**(3.3)**	**(1.5)**	**0.1**	**(3.4)**	**(3.4)**	**(4.5)**	**(11.2)**
Beginning cash and equivalents	**18.4**	**21.2**	**18.1**	**20.3**	**18.4**	**18.1**	**12.7**	**10.9**	**11.0**	**18.1**	**8.6**	**2.9**	**6.6**	**10.3**	**8.6**	**7.0**	**7.1**	**3.7**	**0.3**	**7.0**
Ending cash and equivalents	**21.2**	**18.1**	**20.3**	**18.1**	**18.1**	**12.7**	**10.9**	**11.0**	**8.6**	**8.6**	**2.9**	**6.6**	**10.3**	**7.0**	**7.0**	**7.1**	**3.7**	**0.3**	**(4.2)**	**(4.2)**

Source: Company reports and Ascendiant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Plus Therapeutics, Inc.



Source: https://bigcharts.marketwatch.com/

Report	Report Date	Rating	Price Target
24	3/14/2018	B	4,875.00
25	5/11/2018	B	4,125.00
26	8/15/2018	B	750.00
27	11/21/2018	B	675.00
28	1/18/2019	B	675.00
29	4/1/2019	B	600.00
30	5/16/2019	B	525.00
31	8/22/2019	B	180.00
32	11/24/2019	B	112.50
33	1/31/2020	B	105.00
34	4/1/2020	B	75.00
35	5/17/2020	B	71.25
36	8/11/2020	B	75.00
37	10/29/2020	B	78.75
38	2/26/2021	B	90.00
39	4/25/2021	B	93.75
40	8/7/2021	B	97.50
41	11/21/2021	B	105.00
42	3/15/2022	B	90.00
43	5/2/2022	B	82.50
44	8/6/2022	B	75.00
45	11/6/2022	B	78.75
46	3/7/2023	B	75.00
47	5/11/2023	B	30.00
48	9/4/2023	B	26.00
49	12/8/2023	B	21.00
50	3/9/2024	B	22.00

- Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approval for commercial sale, failure to obtain suitable reimbursement, competition, and changing macroeconomic factors.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of April 15, 2024)

			Investment Banking Services Past 12 months	
Rating	**Count**	**Percent**	**Count**	**Percent**
Buy	55	98%	18	33%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	56	100%	18	32%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.